SCHEMBL3521096

SCHEMBL3521096

CCOCCCCCCCCN

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 9/20 0.48
TSHR P16473 2/20 0.48
ALDH1A1 P00352 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
EPHX1 P07099 1/20 0.48
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA3 P07451 2/20 0.44
CA4 P22748 2/20 0.44
CA6 P23280 2/20 0.44
CA5A P35218 2/20 0.44
CA7 P43166 2/20 0.44
CA9 Q16790 2/20 0.44
CA14 Q9ULX7 2/20 0.44
CA5B Q9Y2D0 2/20 0.44
LMNA P02545 1/20 0.44
BLM P54132 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29380421 1.00 DNM1 (0.48) DNM1TSHRALDH1A1MEN1KMT2A
SCHEMBL8076638 1.00 DNM1 (0.48) DNM1TSHRALDH1A1MEN1KMT2A
SCHEMBL453343 1.00 DNM1 (0.48) DNM1TSHRALDH1A1MEN1KMT2A
SCHEMBL8076864 1.00
SCHEMBL11559711 1.00 DNM1 (0.48) DNM1TSHRALDH1A1MEN1KMT2A
SCHEMBL23961282 1.00 DNM1 (0.48) DNM1TSHRALDH1A1MEN1KMT2A
SCHEMBL8078522 1.00 DNM1 (0.48) DNM1TSHRALDH1A1MEN1KMT2A
SCHEMBL8078232 1.00 DNM1 (0.48) DNM1TSHRALDH1A1MEN1KMT2A
SCHEMBL22577021 1.00 DNM1 (0.48) DNM1TSHRALDH1A1MEN1KMT2A
SCHEMBL25601546 1.00 DNM1 (0.48) DNM1TSHRALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2161318-A1 TRIPHENYLBORON COMPOUND-CONTAINING ANTIFOULING COATING COMPOSITION HAVING IMPROVED STABILITY, ANTIFOULING AGENT SET USED THEREFOR, AND METHOD FOR SUPPRESSING/CONTROLLING DECOMPOSITION OF TRIPHENYLBORON COMPOUND CHUGOKU MARINE PAINTS, LTD. (JP) 2010-03-10 EP claimed
US-20250034139-A1 AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY PHARMA CINQ, LLC 2025-01-30 US disclosed
US-12139483-B2 Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity PHARMA CINQ, LLC (US) 2024-11-12 US disclosed
CN-113574041-B Bisphenol production method and polycarbonate resin production method 三菱化学株式会社 2023-10-13 CN disclosed
WO-2022181298-A1 WATER-BASED ANTIFOULING PAINT COMPOSITION, ANTIFOULING COATING FORMED USING SAME, AND FISHING NET, SHIP, AND UNDERWATER STRUCTURE HAVING COATING ON SURFACE バッセル化学株式会社 2022-09-01 WO disclosed
CN-113574041-A Method for producing bisphenol and method for producing polycarbonate resin 三菱化学株式会社 2021-10-29 CN disclosed
US-20210163476-A1 IMIDAZOQUINOLYL COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY PHARMA CINQ, LLC 2021-06-03 US disclosed
US-10934284-B2 Aminoquinazoline compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity WELLSTAT THERAPEUTICS CORPORATION (US) 2021-03-02 US disclosed
CN-108250142-B Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity 维尔斯达医疗公司 2021-01-26 CN disclosed
WO-2020189201-A1 METHOD FOR PRODUCING BISPHENOL AND METHOD FOR PRODUCING POLYCARBONATE RESIN 三菱ケミカル株式会社 2020-09-24 WO disclosed
WO-2008031525-A1 HYALURONIC ACID DERIVATIVES OBTAINED VIA 'CLICK CHEMISTRY' CROSSLINKING FIDIA FARMACEUTICI S.P.A. (IT) 2008-03-20 WO disclosed
EP-1667734-A2 OPTICAL IMAGING OF COLORECTAL CANCER GE Healthcare AS (NO) 2006-06-14 EP disclosed
WO-2005030266-A2 OPTICAL IMAGING OF COLORECTAL CANCER AMERSHAM HEALTH AS (NO) 2005-04-07 WO disclosed
EP-1404371-A2 PEPTIDE-BASED COMPOUNDS FOR TARGETING INTERGIN RECEPTORS Amersham Health AS (NO) 2004-04-07 EP disclosed
EP-1347784-A2 SIMULTANEOUS DUAL ISOTOPE IMAGING OF CARDIAC PERFUSION AND CARDIAC INFLAMMATION Bristol-Myers Squibb Pharma Company (US) 2003-10-01 EP disclosed
WO-2003006491-A2 PEPTIDE-BASED COMPOUNDS FOR TARGETING INTERGIN RECEPTORS AMERSHAM HEALTH AS (NO) 2003-01-23 WO disclosed
WO-2002036173-A2 SIMULTANEOUS DUAL ISOTOPE IMAGING OF CARDIAC PERFUSION AND CARDIAC INFLAMMATION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2002-05-10 WO disclosed
EP-0846679-B1 Process for preparing 1,3-disubstituted urea SUMIKA FINE CHEMICALS CO LTD (JP) 2000-09-06 EP disclosed
US-5902899-A Process for preparing 1, 3-disubstituted urea SUMIKA FINE CHEMICALS CO., LTD. (JP) 1999-05-11 US disclosed
EP-0846679-A2 Process for preparing 1,3-disubstituted urea SUMIKA FINE CHEMICALS Co., Ltd. (JP) 1998-06-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163476-A1 IMIDAZOQUINOLYL COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY NOD1, NLRP3, AADAC DNM1 2927/4885TSHR 4470/4885ALDH1A1 2980/4885
US-20250034139-A1 AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY AADAC, CASP1, AAAS DNM1 2988/4885TSHR 4205/4885ALDH1A1 2393/4885
US-12139483-B2 Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity NOD1, NLRP3, AADAC DNM1 2927/4885TSHR 4470/4885ALDH1A1 2980/4885
US-10934284-B2 Aminoquinazoline compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity AAAS, AADAC, NFKBIA DNM1 2531/4885TSHR 4755/4885ALDH1A1 3402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.